search
Back to results

Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.

Primary Purpose

Gastroesophageal Reflux Disease

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Pantoprazole
Pantoprazole
placebo
Sponsored by
Southern Arizona VA Health Care System
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastroesophageal Reflux Disease focused on measuring heartburn, acid reflux, GERD, spectrum analysis, electroencephalogram, esophagitis, peptic

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 18 to 80 yrs of age
  • 2 to 3 episodes of GERD/week
  • erosive esophagitis or abnormal 24 hr pH
  • able to read and understand, complete questionnaires

Exclusion Criteria:

  • barrett's esophagus or peptic stricture on endoscopy
  • normal EGD and normal 24 hour pH
  • previous upper GI surgery
  • comorbidity (cardiovascular, respiratory, renal, hepatic)
  • use of narcotics or pain medication on regular basis
  • insomnia, shift work sleep disorder, sleep apnea, restless leg syndrome
  • diabetes, scleroderma or neuromuscular disorders

Sites / Locations

  • Southern Arizona VA Health Care System

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Pantoprazole

placebo

Arm Description

40 mg once daily for four weeks improves sleep quality in patients with GERD

To determine if treatment with pantoprazole 40 mg once daily vs placebo improves sleep outcome in patients with GERD.

Outcomes

Primary Outcome Measures

Symptom control after 4 weeks of treatment.
To determine if treatment with pantoprazole 40 mg daily vs placebo improves sleep quality in patients with GERD.

Secondary Outcome Measures

Effect of Pantoprazole 40 mg Daily vs Placebo on the Power Spectral Analysis of the Sleep Electroencephalogram of Patients With GERD.
To determine if treatment with pantoprazole 40 mg once daily vs placebo improves sleep outcome in patients with GERD using spectral analysis of sleep electroencephalogram.

Full Information

First Posted
May 5, 2008
Last Updated
August 18, 2010
Sponsor
Southern Arizona VA Health Care System
search

1. Study Identification

Unique Protocol Identification Number
NCT00674245
Brief Title
Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.
Official Title
The Effect Of Pantoprazole 40 mg Once Daily Versus Placebo On The Power Spectral Analysis Of The Sleep Electroencephalogram (EEG) Of Patients With Gastroesophageal Reflux Disease (GERD)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2010
Overall Recruitment Status
Completed
Study Start Date
April 2008 (undefined)
Primary Completion Date
July 2010 (Actual)
Study Completion Date
July 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Southern Arizona VA Health Care System

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this research study is to determine if treatment with pantoprazole 40 mg daily versus a placebo improves sleep quality in patients with gastroesophageal reflux disease (GERD). Another purpose is to determine if treatment with pantoprazole 40 mg once daily versus a placebo improves sleep outcomes in patients with gastroesophageal reflux disease using spectral analysis of sleep electroencephalogram (EEG).
Detailed Description
It appears that the presence of intraesophageal stimuli alone may not be sufficient to elicit symptoms of heartburn. Most acid reflux events (>80%-90%) do not reach conscious level and thus are not perceived.[3] It is yet to be determined what factors enhance our perception of esophageal stimuli and may help to elevate them to the conscious level. In recent years, central and peripheral factors that may enhance our perception of intraesophageal stimuli have been evaluated. Intraduodenal fat infusion was shown to enhance perception of intraesophageal acid in patients with GERD.[4] This study suggested that fat is an important modulator of postprandial GERD symptoms. Central factors, such as stress and psychological comorbidity, also appear to have an important role in symptom generation in patients with GERD, regardless if esophageal inflammation is present or absent.[5-8] Thus, by modulating brain-gut interactions, perception of pathological and probably physiological events in the esophagus of patients with GERD may be altered. Poor sleep is a central factor that may enhance perception of intraesophageal stimuli and thus elevate them to the conscious level. Several studies have demonstrated that patients with fibromyalgia or irritable bowel syndrome report increased symptoms due to sleep abnormalities.[9, 10] Similar reports in patients with GERD are not available. A subset of patients with GERD experience nocturnal heartburn that may awaken them during the night. In others, despite lack of nocturnal symptoms, sleep abnormalities may occur due to acid reflux events. In both cases, GERD leads to poor sleep, and that in turn may enhance perception of intraesophageal stimuli, leading to reports of increased frequency and severity of perceived GERD symptoms. Thus, poor sleep may be a crucial factor in symptom generation and exacerbation of patients with GERD. Recently, we have used a novel technique, power spectral analysis of the sleep electroencephalogram (EEG), to assess patients with heartburn and erosive esophagitis and those with heartburn but without erosive esophagitis.[11] We were able to show that among heartburn patients with GERD, EEG spectral power during sleep is shifted towards higher frequencies as compared to heartburn patients without GERD despite similar sleep architecture. Several recent therapeutic trials in GERD patients have failed to demonstrate improvement in polysomnographic studies despite improvement in GERD-related symptoms and subjective reports of sleep quality.[12] Spectral analysis of the sleep EEG might be a more sensitive tool than polysomnographic study in assessing objective improvement of sleep in patients receiving antireflux treatment. In summary, sleep disturbances in patients with GERD are poorly recognized and rarely elicited during clinic visits despite their significant impact on patients' quality of life and probably perception of disease severity. Several studies have demonstrated improvement of subjective reports of sleep quality in patients with GERD receiving antireflux treatment. However, the effect of potent antireflux therapy on objective sleep parameters has yet to be demonstrated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroesophageal Reflux Disease
Keywords
heartburn, acid reflux, GERD, spectrum analysis, electroencephalogram, esophagitis, peptic

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Pantoprazole
Arm Type
Active Comparator
Arm Description
40 mg once daily for four weeks improves sleep quality in patients with GERD
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
To determine if treatment with pantoprazole 40 mg once daily vs placebo improves sleep outcome in patients with GERD.
Intervention Type
Drug
Intervention Name(s)
Pantoprazole
Other Intervention Name(s)
Protonix, PPI
Intervention Description
40 mg once daily for 4 weeks
Intervention Type
Drug
Intervention Name(s)
Pantoprazole
Other Intervention Name(s)
Protonix, PPI
Intervention Description
40 mg once daily improves sleep quality in patients with GERD.
Intervention Type
Drug
Intervention Name(s)
placebo
Other Intervention Name(s)
sugar pill
Intervention Description
40 mg once daily for 4 weeks
Primary Outcome Measure Information:
Title
Symptom control after 4 weeks of treatment.
Description
To determine if treatment with pantoprazole 40 mg daily vs placebo improves sleep quality in patients with GERD.
Time Frame
April 2008 to July 2010
Secondary Outcome Measure Information:
Title
Effect of Pantoprazole 40 mg Daily vs Placebo on the Power Spectral Analysis of the Sleep Electroencephalogram of Patients With GERD.
Description
To determine if treatment with pantoprazole 40 mg once daily vs placebo improves sleep outcome in patients with GERD using spectral analysis of sleep electroencephalogram.
Time Frame
April 2008-July 2010

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 18 to 80 yrs of age 2 to 3 episodes of GERD/week erosive esophagitis or abnormal 24 hr pH able to read and understand, complete questionnaires Exclusion Criteria: barrett's esophagus or peptic stricture on endoscopy normal EGD and normal 24 hour pH previous upper GI surgery comorbidity (cardiovascular, respiratory, renal, hepatic) use of narcotics or pain medication on regular basis insomnia, shift work sleep disorder, sleep apnea, restless leg syndrome diabetes, scleroderma or neuromuscular disorders
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ronnie Fass, MD
Organizational Affiliation
Southern VA Health Care System
Official's Role
Principal Investigator
Facility Information:
Facility Name
Southern Arizona VA Health Care System
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85723
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
10811327
Citation
Fass R, Fullerton S, Tung S, Mayer EA. Sleep disturbances in clinic patients with functional bowel disorders. Am J Gastroenterol. 2000 May;95(5):1195-2000. doi: 10.1111/j.1572-0241.2000.02009.x.
Results Reference
background
PubMed Identifier
10027672
Citation
Wiklund IK, Junghard O, Grace E, Talley NJ, Kamm M, Veldhuyzen van Zanten S, Pare P, Chiba N, Leddin DS, Bigard MA, Colin R, Schoenfeld P. Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl. 1998;(583):41-9.
Results Reference
background
PubMed Identifier
15679759
Citation
Orr WC, Goodrich S, Robert J. The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux. Aliment Pharmacol Ther. 2005 Jan 15;21(2):103-8. doi: 10.1111/j.1365-2036.2005.02310.x.
Results Reference
background
PubMed Identifier
9136821
Citation
Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997 May;112(5):1448-56. doi: 10.1016/s0016-5085(97)70025-8.
Results Reference
background
PubMed Identifier
10507956
Citation
Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999 Oct 5;131(7):485-91. doi: 10.7326/0003-4819-131-7-199910050-00002.
Results Reference
background
PubMed Identifier
8404401
Citation
Goldsmith G, Levin JS. Effect of sleep quality on symptoms of irritable bowel syndrome. Dig Dis Sci. 1993 Oct;38(10):1809-14. doi: 10.1007/BF01296103.
Results Reference
background

Learn more about this trial

Effect of Pantoprazole 40mg Daily vs Placebo on Power Spectral Analysis of the Sleep EEG of Patients With GERD.

We'll reach out to this number within 24 hrs